Saturday 17 October 2026
Export QSI’s income statement to Excel — free account
Quantum-Si Incorporated
QSI Healthcare Medical Devices
Quantum-Si Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $2.4 million, down 20.3% from fiscal 2024. In the quarter to June 2026, revenue fell 41.8%, EPS grew 31.3% and free cash flow grew 9.75%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.12
0.19
−14.50%
Follow QSI
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | 2 |
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | 265.10 | 126.43 | 89.30 |
Altman Z-Score |
— | — | — | — | — | 3.87 | 3.31 | 0.36 |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | 8.39 | 1.47 | 0.75 |
Beneish M-Score |
— | — | — | — | — | — | (1.07) | 2.00 |
P/Operating CF |
— | — | — | — | — | (13.68) | (16.90) | (13.31) |
P/B ratio |
— | — | — | — | — | 1.06 | 1.79 | 0.99 |
Price to Tangible BV |
— | — | — | — | — | 1.06 | 1.80 | 0.99 |
EV/Sales |
— | — | — | — | — | 26.90 | 57.89 | 22.43 |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | (0.31) | (2.02) | (0.58) |
EV/FCF |
— | — | — | — | — | (0.29) | (1.92) | (0.56) |
Quick Ratio |
— | — | 13.60 | 40.96 | 22.38 | 22.23 | 11.60 | 7.30 |
Current Ratio |
— | — | 13.75 | 41.39 | 22.81 | 22.94 | 11.99 | 7.64 |
Net Debt/EBITDA |
— | 0.00 | 0.98 | 4.92 | 3.14 | 2.41 | 1.87 | 1.36 |
Debt/Assets |
0.00% | 0.00% | 4.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | (0.01) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 |
Operating CF/Net income |
— | 0.86 | 0.89 | 0.70 | 0.68 | 0.98 | 0.87 | 0.93 |
Capex/Depreciation |
— | (1.59) | (0.52) | (5.54) | (0.89) | (1.27) | 1.22 | 0.71 |
Interest Coverage |
— | — | (4,076.78) | (19,381.60) | — | — | — | — |
| — | 0.00% | (23.08%) | (59.87%) | (31.69%) | (30.45%) | (41.48%) | (46.52%) | |
| — | 0.00% | (180.40%) | (34.93%) | (29.61%) | (27.83%) | (36.99%) | (41.07%) | |
ROIC |
— | 0.00% | 0.00% | (1,057.02%) | (1,046.38%) | (500.48%) | (1,166.58%) | (126.60%) |
Return on Tangible Assets |
— | 0.00% | (98.69%) | (20.02%) | (36.86%) | (35.41%) | (46.80%) | (61.04%) |
Average Days of Receivables |
— | — | 0.00 | 0.00 | 0.00 | 124.14 | 159.11 | 779.00 |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 6,194.55% | 1,950.33% | 2,206.86% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 4,125.14% | 1,652.55% | 1,837.19% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 787.06% | 290.61% | 442.24% |
Graham Net Nets |
— | — | — | — | — | 0.84 | 0.48 | 0.69 |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | (33.50%) | (26.30%) | (47.27%) |
Free Cash Flow Yield |
— | — | — | — | — | (34.62%) | (23.91%) | (44.70%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.01 |
Operating CF per Share |
— | (5.97) | (6.08) | (0.84) | (0.65) | (0.67) | (0.61) | (0.48) |
Capex per Share |
— | (0.24) | (0.09) | (0.07) | (0.08) | (0.04) | (0.03) | (0.01) |
Free Cash Flow per Share |
— | (6.21) | (6.17) | (0.91) | (0.73) | (0.70) | (0.65) | (0.49) |
Cash per Share |
— | 0.00 | 6.89 | 5.92 | 2.52 | 1.82 | 1.46 | 0.82 |
Shareholders Equity per Share |
— | 0.00 | (29.82) | 5.99 | 2.58 | 1.92 | 1.50 | 1.11 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 0.00 | (29.82) | 5.99 | 2.58 | 1.92 | 1.50 | 1.11 |
Free Cash Flow |
— | (31.95) | (33.03) | (72.58) | (101.30) | (99.31) | (92.44) | (97.23) |
Working Capital |
— | — | 35.10 | 465.64 | 342.48 | 254.70 | 199.82 | 152.84 |
Capital Expenditures |
— | (1.24) | (0.46) | (5.76) | (10.74) | (5.27) | (4.64) | (2.52) |
Net Current Asset Value |
— | 0.00 | (162.46) | 450.98 | 325.40 | 239.68 | 185.56 | 150.48 |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 4.87 | 1.52 | 1.03 |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | 0.00 | 0.45 | 0.12 | 0.72 | 0.26 | (0.24) | (0.27) |
Cash ROIC |
— | 0.00% | 27.29% | (7.65%) | (14.27%) | (18.76%) | (21.75%) | (25.38%) |
Accounts Receivable Turnover |
— | — | 0.00 | 0.00 | 0.00 | 3.77 | 3.60 | 0.75 |
Accounts Payable Turnover |
— | — | 0.38 | 0.44 | 0.71 | 0.21 | 0.79 | 0.72 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.36 | 0.35 |
Average Days of Payables |
— | — | 542.60 | 1,189.67 | 551.31 | 1,085.17 | 483.41 | 461.73 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | 2,424.12 | 1,018.14 | 909.51 |
Average Receivables |
— | — | 0.71 | 0.71 | 0.54 | 0.29 | 0.85 | 3.27 |
Average Payables |
— | — | 2.36 | 2.36 | 3.65 | 2.83 | 1.85 | 1.78 |
Average Inventory |
— | — | — | — | — | — | 4.01 | 3.63 |
Average Assets |
— | 0.00 | 20.30 | 271.91 | 447.36 | 344.87 | 273.06 | 246.74 |
Average Common Equity |
— | — | 158.65 | 158.65 | 417.87 | 315.16 | 243.52 | 217.82 |
Columns are period end dates